Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Treasury Shares (2016 - 2025)

Spyre Therapeutics' Treasury Shares history spans 10 years, with the latest figure at $76932.0 for Q4 2025.

  • For Q4 2025, Treasury Shares fell 33.33% year-over-year to $76932.0; the TTM value through Dec 2025 reached $76932.0, down 33.33%, while the annual FY2025 figure was $76932.0, 33.33% down from the prior year.
  • Treasury Shares reached $76932.0 in Q4 2025 per SYRE's latest filing, down from $115398.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $190000.0 in Q4 2021 to a low of $5660.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $132919.4, with a median of $151932.5 recorded in 2022.
  • Peak YoY movement for Treasury Shares: plummeted 97.02% in 2022, then surged 2618.46% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $190000.0 in 2021, then tumbled by 97.02% to $5660.0 in 2022, then soared by 2618.46% to $153865.0 in 2023, then decreased by 25.0% to $115398.0 in 2024, then tumbled by 33.33% to $76932.0 in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Treasury Shares are $76932.0 (Q4 2025), $115398.0 (Q4 2024), and $153865.0 (Q4 2023).